Rina-S led to a 50% response rate, including two complete responses, in heavily pretreated advanced endometrial cancer, ...

A study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that combining the immunotherapy drug ...

For decades, gynecologic cancer treatment has used aggressive surgical intervention and chemotherapy. These methods often ...

The trial evaluated the combination of GSK’s Jemperli and Zejula as a first-line therapy for stage III and IV epithelial OC.

A study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that combining the immunotherapy drug dostarlimab with ...

"Advanced stage and recurrent endometrial cancer often lead to resistance to standard of care options. When this occurs, prognosis worsens and treatment options become increasingly limited, leaving ...

This week’s loving giving local donation goes to an organization that helps women and men in the fight against cancer. It all started with Paula’s story and now it’s ...

Investing.com -- Genmab (NASDAQ: GMAB) has unveiled new data for its cancer drug Rina-S, which is being tested for use in endometrial cancer. This follows promising early results from trials in ...

The NDA is supported by data from FRUSICA-2, a randomized, open-label, active-controlled registration study evaluating the ...

Genmab A/S (NASDAQ:GMAB) has announced promising new data for its investigational antibody-drug conjugate, rinatabart ...

Genmab (NASDAQ:GMAB) has released new findings regarding its cancer therapy Rina-S, currently under investigation for ...

Endometrial cancer (EC) is the most common gynecologic cancer in developed ... Randomized Trials of Adjuvant CT in EC* For patients already treated with platinum-based CT, retreatment with ...